Objectives To perform a systematic review to determine the effectiveness of interventions designed to reduce potentially inappropriate prescribing (PIP) in community-dwelling older people.
Introduction
Older people are among the highest consumers of prescription medication and evidence suggests that prescribing in this population can be potentially inappropriate.
1 Potentially inappropriate prescribing (PIP) comprises a number of suboptimal prescribing practices including inappropriate dose or duration of medications, drug-drug interactions, drugdisease interactions and the use of medications that carry a significant risk of an adverse drug event (ADE). 1, 2 Older people are more likely to have multimorbidity and be taking a number of medications (polypharmacy) and consequently, are more vulnerable to medication errors, adverse events and PIP.
Several criteria have been developed to quantify the appropriateness of prescribing. These criteria can be categorised as either explicit (criterion-based) or implicit (judgement-based).
Explicit criteria are specific statements of appropriateness that are generally drug or disease orientated and commonly focus on specific drugs to avoid. 1 The US Beers criteria are the most commonly used explicit criteria for measuring PIP, 3 and the European Screening Tool for Older Peoples Prescriptions (STOPP) criteria has become increasingly popular in recent years. 4 Implicit measures are based on clinical judgement. The most commonly used implicit criteria is the Medicines Appropriateness Index (MAI), which assesses the appropriateness of prescribing across 10 elements: indication, effectiveness, dose, correct directions, practical directions, drug-drug interactions, drug-disease interactions, duplication, duration and cost. 5 The scale of the PIP problem has been well documented in older patients using both explicit and implicit criteria, with the prevalence of PIP in community dwelling older patients estimated to be anywhere between 20 and 50%. 6-8 PIP has been found to be associated with increased morbidity, ADEs, lower health related quality of life, hospitalisations and expenditure. 7, 9-11
As global populations age, PIP in older people is an important public health concern, particularly in primary care where the majority of prescribing for older people takes place. A number of interventions have been developed and tested to reduce PIP across healthcare settings. Recent systematic reviews have examined the evidence on interventions to decrease PIP in nursing home settings. 12-15 These reviews have produced mixed results, and due to the heterogeneity of included studies, robust conclusions about the effectiveness of such intervention are lacking. [13] [14] [15] Where strategies were found to be effective within the hospital or nursing home setting, there is little evidence to suggest that these would be effective for community dwelling older patients. The aim of this systematic review is to identify and determine the effectiveness of interventions to reduce PIP in community dwelling older people.
Methods
The PRISMA guidelines for the conduct and reporting of systematic reviews and metaanalyses were adhered to in the conduct of this systematic review. 
Study selection and data extraction
Studies were included if they met the following inclusion criteria:
1. Included community dwelling older adults (≥65 years or had an average age of ≥65 years) as the population of interest. Studies where >20% of the subject population were described as institutionalised (e.g. nursing homes, residential care homes or geriatric inpatients) were excluded.
2. An intervention intended to improve PIP in primary care, including but not restricted to: organisational, professional, financial, regulatory or multifaceted interventions compared to usual care or alternate intervention (see Table 1 for definitions).
3. The primary outcome was change in PIP measured using specified implicit or explicit tools (e.g. Beers, STOPP, MAI). Studies that focussed on the reduction of inappropriate prescribing in one drug class only were also excluded.
4. Study design was randomised controlled trials (RCT) only.
No language restrictions were applied. Studies were assessed against the inclusion criteria by three reviewers (AQ, CH, CF) by reading titles and/or abstracts. Eligible studies were read fully in duplicate and their suitability for inclusion was independently determined (RG, BC).
Disagreement was managed by consensus. Data were extracted on study characteristics (setting, duration, outcome etc.) and participant demographics (age, gender etc.). Where available, data on secondary outcomes such as patient reported health status (e.g.
psychosocial outcomes: quality of life, psychological health: well-being, physical health:
adverse drug events), health behaviour (e.g. medication compliance) and resource use (e.g.
health service utilisation, costs) were extracted.
Data synthesis
The studies identified were too heterogeneous in terms of their outcome measures and intervention types to conduct a meta-analysis so a narrative summary was performed.
Where appropriate, crude odds ratios and absolute risk reductions (ARR) were calculated.
Interventions were categorised by the standard taxonomy of interventions developed by
The Cochrane Effective Practice and Organization of Care Group (EPOC) including organisational, professional, financial and regulatory interventions, with the addition of multifaceted interventions (Table 1) .
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Ongoing studies
Where published protocols were identified during the search, study authors were contacted to ascertain if results were available for inclusion in the review. Where results were not available, ongoing studies were described in terms of methods, intervention used and outcome measures, together with an estimate of the reporting date, where available (Appendix 1).
Assessment of risk of bias
Three authors (BC, CH, AQ) independently assessed risk of bias using the Cochrane
Collaboration's risk of bias tool including the standard domains of sequence generation, allocation concealment, blinding, outcome data, selective outcome reporting, protection against contamination, performance of baseline measurement and sample size. In cases of disagreement, a fourth reviewer (RG) was consulted. Some of the review authors were involved in the conduct of an RCT included in this review (the OPTI-SCRIPT study). The data extraction and methodological quality assessment was conducted independently by a researcher not involved in the review team (LM).
Results
Included studies
749 unique records were screened, and 30 full texts were reviewed. 11 RCTs met the inclusion criteria (Figure 1 ). Two studies were identified from conference abstracts/published protocols, one of which the review authors were involved in so study information was available, bringing the total of included studies to 12. The study author was contacted for details on the second protocol identified (Appendix 1).
Study description
Six studies were conducted in North America, 18-23 five in Europe, [24] [25] [26] [27] [28] and one in New
Zealand. 29 The mean age of the 156,529 included patients ranged from 65 to 81 years (Table   2 ). Participants were eligible if they were community dwelling in all studies, had polypharmacy (defined as ≥3 or ≥5 drugs) in five studies 18, 19, 24, 25, 29 and were at high risk for medication-related adverse events in one study. 23 Included studies consisted of five patient randomised designs with sample sizes ranging from 81 to 59,860, 18-20, 23, 26 and seven cluster studies with 13 to 107 clusters randomised. 21, 22, 24, 25, [27] [28] [29] All but three studies compared the intervention to usual care (Table 2) . 21, 25, 27 Three studies made reference to intervention design, 20, 27, 28 with one study publishing the intervention design and pilot process separately, referencing a specific theoretical framework for the intervention design.
28, 30
Process evaluations to explore intervention implementation and enactment were conducted in three studies. 18, 19, 28 All studies were funded by government bodies, university departments or professional bodies.
PIP measurement
Baseline PIP prevalence ranged from 18% to 100%. PIP was measured using implicit criteria in four studies and eight studies used explicit criteria. 
Risk of bias
Studies were heterogeneous with regard to risk of bias ( Figure 2 
Effects on medication appropriateness by intervention category
All studies could be divided into organisational (n=6), professional (n=2) or multifaceted interventions (n= 4) ( Table 2) . No study involved financial or regulatory interventions.
Organisational interventions
The six organisational studies included four pharmacist interventions, 19 however, no effect on the discontinuation of existing PIP was noted.
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Multifaceted interventions
Four multifaceted (combining two or more techniques) interventions were identified.
21, 24, 27, 28 Rognstad et al found peer academic detailing with audit and feedback to be effective in reducing PIP (10.3%, 95% CI 5.9 -15.0 reduction relative to baseline). 27 The largest reductions were seen for drugs such as tricyclic antidepressants (TCAs) and 'old'
antihistamines. 27 The OPTI-SCRIPT study also found that PIP was reduced by academic detailing, medicines review with web-based pharmaceutical treatment algorithms that provided alternative treatment options, and tailored patient information leaflets, particularly in the appropriate prescribing of proton pump inhibitor (adjusted OR 0.3, 95% CI 0.1 -0.7). 28 In a population where drug-specific alerts were in operation, Simon et al analysed the effect of age-specific computerised alerts alone, and in combination with intensive academic detailing. 21 They found that age-specific alerts resulted in a continuation of the effects of drug-specific alerts. Group academic detailing did not enhance the effect of the alerts. Using implicit criteria, Bregnhoj et al found a combined educational meeting with prescribing feedback resulted in a mean overall MAI change of -5.
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Effects on secondary outcomes: patient health status and behaviour
Three pharmacist interventions studies involving medication review, found no significant benefit on the psychosocial outcome of patient quality of life (SF-36). 19, 23, 29 In the only study powered to detect a difference, Bryant et al noted a significant decrease in the SF-36
domains of emotional role and social functioning in the intervention group which they attributed to the high withdrawal rate of pharmacists in the study leaving patients feeling abandoned. 29 One multifaceted intervention had no significant effect on patient psychological health in terms of well-being (WBQ-12). Pharmacist interventions had no significant impact on the physical health outcome of ADEs in one study.
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In terms of patient behaviour, one multifaceted intervention had no significant effect on beliefs about medication necessity. 28 One of two pharmacist intervention studies reported a significant improvement in medication compliance 19, 23 .
Effects on secondary outcomes: health service utilisation and resource use (costs)
Health service utilisation was assessed in two studies, 23, 28 with one reporting a reduction in hospitalisations but not emergency department visits. 23 The data analysis is ongoing in the second study. 28 Two studies conducted economic evaluations. Denneboom et al found that both shared pharmaceutical care and written feedback showed modest savings regarding medication costs but this was not statistically significant. 25 The data analysis is ongoing in the second study.
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Process evaluations
Of three process evaluations conducted, two incorporated quantitative and qualitative data. 19, 28 All studies assessed intervention implementation 18, 19, 28 with one study finding that two of the three components of a multifaceted intervention were utilised. Physicians were receptive to the intervention in two studies.
This systematic review identified 12 RCTs of interventions to reduce PIP in community dwelling older people. There was considerable variation in the types of interventions with small numbers of studies grouped together. Overall, four out of six organisational interventions reported an improvement in PIP, particularly through pharmacists conducting medication reviews. The evidence for the effectiveness of MDTs was weak. Both professional interventions were CDSS studies and were effective in decreasing new PIP but not existing PIP. Three out of four multifaceted approaches were effective in reducing PIP.
A variety of interventions can be effective in improving prescribing practice and medication safety, including CDSS, educational outreach and audit and feedback. 31-34 Consistent with these findings and previous reviews of PIP specific interventions in other healthcare settings, this review found various strategies may be useful in reducing PIP. 1, 12, 15, 35 This would suggest that PIP is amenable to change, however, there was a range of modest effect sizes. Regardless of the explicit criteria utilised, absolute risk reductions of less than 3%
were common. The largest absolute risk reduction was 25% in a study where all participants had PIP at baseline. 28 There was evidence to suggest that certain drug classes responded better to certain interventional strategies as TCAs and 'old' antihistamines were reduced by multifaceted interventions, 27 and CDSS, 20 while appropriate prescribing of proton pump inhibitors improved with a multifaceted intervention. 28 In all studies, these drugs were the most frequently occurring in the patient population so a significant effect was arguably more likely to be found. Both CDSS studies were effective in decreasing the initiation of PIP,
but not the discontinuation of existing PIP, while three pharmacist medication review studies were effective in increasing the appropriateness of current prescribing. Few studies examined the impact of interventions on patient outcomes or patient preferences, which may be of greater importance to patients overall. This may reflect the difficulty in selecting such outcomes as until the recent publication of the CONSORT guidelines on patient-reported outcomes in RCTs, guidance has been lacking. 37 Three studies that demonstrated an improvement in MAI scores using a pharmacist intervention did not report an effect on quality of life or ADEs. 19, 23, 29 While higher MAI scores have been found to be associated with ADEs, 38 there is little evidence to suggest that a decrease in MAI score equates to a decrease in adverse outcomes. It remains unclear if this is an effect of the studies being underpowered to detect differences in patient outcomes, the follow-up period being too short to detect a difference, or the outcome measures not being responsive to the intervention.
While various strategies may reduce PIP, little attention has been paid to understanding how or why interventions worked or failed. In order to develop feasible and appropriate interventions, they should be theoretically informed, modelled and pilot tested prior to RCT implementation, and the long-term implementation evaluated. 39 This review has highlighted a deficit in intervention development and evaluation. Little detail on intervention development, underlying theoretical frameworks, and pilot studies was given, even in the more recent publications, a common issue in behaviour change interventions. 40 , 41 Very few studies in this review conducted a process evaluation to gain insight into the intervention implementation. Such evaluations can also offer insights into how study findings can be generalised to other settings. In relation to multifaceted interventions, too few studies were identified to draw conclusions about which combinations of interventions may be most effective.
Strengths and weaknesses of this review
This review is timely as the prevalence of PIP remains high in community dwelling older people. However, there are some limitations. Potential limitations in the search strategy arise from the diversity in MeSH terms and key words used to describe interventions and PIP. Furthermore, publication bias is an important source of potential bias in systematic reviews. RCT designs were included in this review. While this may have resulted in the exclusion of other studies of interest, this criterion allowed for the inclusion of more robust evidence as nonrandomised studies frequently report larger treatment effects than randomised studies. 42 A broad definition of PIP was utilised and studies that focussed on the reduction of inappropriate prescribing in one drug class only were excluded. Due to the heterogeneity of the interventions and their outcome measures, a meta-analysis was not possible. Few studies conducted process evaluations or presented adequate detail which would allow for an analysis of the impact of contextual factors on intervention effectiveness. Usual care can vary greatly across settings and few studies described it in great detail. Many studies were limited by potential bias, particularly in relation to selection bias, and only half of the studies had adequate sample size, undermining the robustness of the findings.
Implications for clinical practice and future research
A significant body of observational research has been published on PIP over the last number of years. There are at least 36 published tools available to assess inappropriate prescribing in older people. 43 Numerous individual studies have utilised these tools to establish the prevalence and outcomes of PIP across healthcare settings. Future research should explore whether the differences in decreasing the initiation of PIP, as opposed to the discontinuation of existing PIP results from differences in the interventions, or differences in applying explicit or implicit criteria.
Conclusions
This review highlights various interventions including organisational (pharmacist interventions), professional (CDSSs) and multifaceted approaches appear beneficial in terms of reducing inappropriate prescribing. However, effects sizes are often small and it is unclear if such interventions can result in clinically significant improvements in patient outcomes.
Future research should place greater emphasis on intervention development and process evaluations to provide rigorous evaluations that will add to understanding how effective interventions can be sustained and ultimately translated into improvements in patient outcomes, particularly in relation to preventing the initiation of PIP drugs.
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Appendix 1: Characteristics of ongoing studies
Cedilnik Group
Title Use of web-based application to improve prescribing in home-living elderly:
A randomised controlled study protocol 45 
Study design
RCT
Participants Home dwelling adults ≥ 65 years
Intervention Web-based application will screen for PIP using STOPP and START criteria.
Identified potentially inappropriate prescriptions will be presented to participants' physicians for consideration and change. 
H high risk L low risk U unclear risk 
